Nonalcoholic Steatohepatitis – Current Treatment – Detailed, Expanded Analysis: Current Treatment: Physician Insights (US)
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s relatively high prevalence. Only off-label medications are available for NASH, a situation that, when combined with the limited awareness of the disease and the challenges in making a diagnosis, translates to low treatment rates. However, new diagnostics and the anticipated launch of the first therapies approved for NASH should have a positive impact on treatment of the disease. Innovative novel therapies, which may include Intercept Pharmaceuticals’ obeticholic acid, Allergan’s cenicriviroc, and Madrigal Pharmaceuticals’ resmetirom, will be able to command high prices, although these agents’ commercial success will likely be determined by how they are adopted into medical practice.
QUESTIONS ANSWERED
What are U.S. specialists’ attitudes toward and perceptions of the diagnosis and treatment of NASH?
How are U.S. hepatologists and gastroenterologists treating NASH patients? What off-label medications are being used?
What are the drivers and constraints determining prescribing practices for NASH?
How could the availability of the first novel branded NASH agents affect the prescribing landscape?
What might emerging NASH drug therapies need to demonstrate to convince prescribers to switch from off-label treatments?
CONTENT HIGHLIGHTS
Geography: United States
Primary research survey of 51 U.S. hepatologists and 50 U.S. gastroenterologists
Factors influencing disease management and treatment decisions.
Drivers of treatment selection.
Physician-reported treatment practices and brand-level patient shares.
Rationale for changes in treatment approach.
Physician insight on persistency and compliance.
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
Nonalcoholic Steatohepatitis - Current Treatment - Detailed, Expanded Analysis: Current Treatment: Physician Insights (US)
Current Treatment Physician Insights Non-alcoholic steatohepatitis US 2022
Sayani Datta, M.Sc.
Sayani Datta, M.Sc., is a principal analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. Her primary area of focus is nonalcoholic steatohepatitis (NASH). She has worked on various types of custom and syndicated research projects in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, commercial opportunity assessments, and market tracking and intelligence. She holds a master of science degree in biotechnology from the University of Leeds, where she gained exposure to life sciences research and development working as a postgraduate research intern.
